Hydroxychloroquine: A new approach of thrombosis in the antiphospholipid syndrome;Hydroxychloroquine: une nouvelle approche thérapeutique des manifestations thrombotiques du syndrome des antiphospholipides

Revue de Medecine Interne

Volumn 31, Issue 12, 2010, Pages 854-857

  Szymezak, J ^a   Ankri, A ^b   Fischer, A M ^a   Darnige, L ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Annexin A5; Antiphospholipid syndrome; Hydroxychloroquine; Systemic lupus erythematosus; Thrombosis

Indexed keywords

HYDROXYCHLOROQUINE; LIPOCORTIN 5; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; IN VITRO STUDY; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ANNEXIN A5; ANTIPHOSPHOLIPID SYNDROME; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; THROMBOSIS; TREATMENT OUTCOME;

EID: 78649524926     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2010.08.018     Document Type: Short Survey

References (32)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309-1311.
3. Darnige L. Diagnostic biologique du syndrome des antiphospholipides. Rev Med Interne 2006, 27:296-301.
4. Pengo V., Tripodi A., Reber G., Rand J.H., Ortel T.L., Galli M., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, 7:1737-1740.
5. Urbanus R.T., Derksen R.H., de Groot PG Platelets and the antiphospholipid syndrome. Lupus 2008, 17:888-894.
6. Pierangeli S.S., Girardi G., Vega-Ostertag M., Liu X., Espinola R.G., Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005, 52:2120-2124.
7. Regnault V., Beguin S., Wahl D., de Maistre E., Coenraad Hemker H., Lecompte T. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost 2003, 89:208-212.
8. Kinev A.V., Roubey R.A. Tissue factor in the antiphospholipid syndrome. Lupus 2008, 17:952-958.
9. Rand J.H., Wu X.X., Andree H.A., Lockwood C.J., Guller S., Scher J., et al. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism. N Engl J Med 1997, 337:154-160.
10. De Laat B., Wu X.X., van Lummel M., Derksen R.H., De Groot P.G., Rand J.H. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007, 109:1490-1494.
11. Rand J.H., Wu X.X., Quinn A.S., Chen P.P., McCrae K.R., Bovill E.G., et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003, 163:1193-1200.
12. Rand J.H., Wu X.X., Quinn A.S., Taatjes D.J. Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus 2008, 17:922-930.
13. Ruiz-Irastorza G., Hunt B.J., Khamashta M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007, 57:1487-1495.
14. Lim W., Crowther M.A., Eikelboom J.W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006, 295:1050-1057.
15. Bates S.M., Greer I.A., Pabinger I., Sofaer S., Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:844S-886S.
16. The Canadian Hydroxychloroquine Study Group A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991, 324:150-154.
17. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., Lechat P., Piette J.C. Hydroxychloroquine in systemic lupus erythematosus. Lancet 2007, 369:1257-1258.
18. Costedoat-Chalumeau N., Leroux G., Amoura Z., Piette J.C. Hydroxychloroquine dans le traitement du lupus: le renouveau. Rev Med Interne 2008, 29:735-737.
19. Costedoat-Chalumeau N., Leroux G., Piette J.C., Amoura Z. Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?. Joint Bone Spine 2010, 77:4-5.
20. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996, 25:191-193.
21. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2009, 69:20-28.
22. Erkan D., Yazici Y., Peterson M.G., Sammaritano L., Lockshin M.D. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002, 41:924-929.
23. Tektonidou M.G., Laskari K., Panagiotakos D.B., Moutsopoulos H.M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009, 61:29-36.
24. Kaiser R., Cleveland C.M., Criswell L.A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009, 68:238-241.
25. Jung H., Bobba R., Su J., Shariati-Sarabi Z., Gladman D.D., Urowitz M., et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010, 62:863-868.
26. Genton E., Gent M., Hirsh J., Harker L.A. Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts). N Engl J Med 1975, 293:1296-1300.
27. Jancinova V., Nosal R., Petrikova M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res 1994, 74:495-504.
28. Espinola R.G., Pierangeli S.S., Gharavi A.E., Harris E.N. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002, 87:518-522.
29. Edwards M.H., Pierangeli S., Liu X., Barker J.H., Anderson G., Harris E.N. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997, 96:4380-4384.
30. Rand J.H., Wu X.X., Quinn A.S., Ashton A.W., Chen P.P., Hathcock J.J., et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010, 115:2292-2299.
31. Rand J.H., Wu X.X., Quinn A.S., Chen P.P., Hathcock J.J., Taatjes D.J. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008, 112:1687-1695.
32. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., Aymard G., Leroux G., Marra D., et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007, 66:821-824.